Literature DB >> 32399778

Genomic Strategies Toward Identification of Novel Therapeutic Targets.

Thorsten Kessler1,2, Heribert Schunkert3,4.   

Abstract

Coronary artery disease, myocardial infarction, and secondary damages of the myocardium in the form of ischemic heart disease remain major causes of death in Western countries. Beyond traditional risk factors such as smoking, hypertension, dyslipidemia, or diabetes, a positive family history is known to increase risk. The genetic factors underlying this observation remained unknown for decades until genetic studies were able to identify multiple genomic loci contributing to the heritability of the trait. Knowledge of the affected genes and the resulting molecular and cellular mechanisms leads to improved understanding of the pathophysiology leading to coronary atherosclerosis. Major goals are also to improve prevention and therapy of coronary artery disease and its sequelae via improved risk prediction tools and pharmacological targets. In this chapter, we recapitulate recent major findings. We focus on established novel targets and discuss possible further targets which are currently explored in translational studies.
© 2020. The Author(s).

Entities:  

Keywords:  Coronary artery disease; Exome sequencing; Genome-wide association studies; Genomics; Myocardial infarction

Mesh:

Year:  2022        PMID: 32399778     DOI: 10.1007/164_2020_360

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  105 in total

1.  Antiinflammatory activity of soluble guanylate cyclase: cGMP-dependent down-regulation of P-selectin expression and leukocyte recruitment.

Authors:  Amrita Ahluwalia; Paul Foster; Ramona S Scotland; Peter G McLean; Anthony Mathur; Mauro Perretti; Salvador Moncada; Adrian J Hobbs
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-23       Impact factor: 11.205

2.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

Authors:  Jonathan C Cohen; Eric Boerwinkle; Thomas H Mosley; Helen H Hobbs
Journal:  N Engl J Med       Date:  2006-03-23       Impact factor: 91.245

3.  Patients with High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit from Alirocumab Treatment in the Odyssey Outcomes Trial.

Authors:  Amy Damask; P Gabriel Steg; Gregory G Schwartz; Michael Szarek; Emil Hagström; Lina Badimon; M John Chapman; Catherine Boileau; Sotirios Tsimikas; Henry N Ginsberg; Poulabi Banerjee; Garen Manvelian; Robert Pordy; Sibylle Hess; John D Overton; Luca A Lotta; George D Yancopoulos; Goncalo R Abecasis; Aris Baras; Charles Paulding
Journal:  Circulation       Date:  2019-11-11       Impact factor: 29.690

4.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.

Authors:  Christopher P Cannon; Michael A Blazing; Robert P Giugliano; Amy McCagg; Jennifer A White; Pierre Theroux; Harald Darius; Basil S Lewis; Ton Oude Ophuis; J Wouter Jukema; Gaetano M De Ferrari; Witold Ruzyllo; Paul De Lucca; KyungAh Im; Erin A Bohula; Craig Reist; Stephen D Wiviott; Andrew M Tershakovec; Thomas A Musliner; Eugene Braunwald; Robert M Califf
Journal:  N Engl J Med       Date:  2015-06-03       Impact factor: 91.245

5.  Effect of mutations in the PCSK9 gene on the cell surface LDL receptors.

Authors:  Jamie Cameron; Øystein L Holla; Trine Ranheim; Mari Ann Kulseth; Knut Erik Berge; Trond P Leren
Journal:  Hum Mol Genet       Date:  2006-03-28       Impact factor: 6.150

6.  Knockout of Adamts7, a novel coronary artery disease locus in humans, reduces atherosclerosis in mice.

Authors:  Daniel J Rader; Muredach P Reilly; Robert C Bauer; Junichiro Tohyama; Jian Cui; Lan Cheng; Jifu Yang; Xuan Zhang; Kristy Ou; Georgios K Paschos; X Long Zheng; Michael S Parmacek
Journal:  Circulation       Date:  2015-02-20       Impact factor: 29.690

7.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia.

Authors:  Marianne Abifadel; Mathilde Varret; Jean-Pierre Rabès; Delphine Allard; Khadija Ouguerram; Martine Devillers; Corinne Cruaud; Suzanne Benjannet; Louise Wickham; Danièle Erlich; Aurélie Derré; Ludovic Villéger; Michel Farnier; Isabel Beucler; Eric Bruckert; Jean Chambaz; Bernard Chanu; Jean-Michel Lecerf; Gerald Luc; Philippe Moulin; Jean Weissenbach; Annick Prat; Michel Krempf; Claudine Junien; Nabil G Seidah; Catherine Boileau
Journal:  Nat Genet       Date:  2003-06       Impact factor: 38.330

8.  Inhibition of Angiopoietin-Like Protein 3 With a Monoclonal Antibody Reduces Triglycerides in Hypertriglyceridemia.

Authors:  Zahid Ahmad; Poulabi Banerjee; Sara Hamon; Kuo-Chen Chan; Aurelie Bouzelmat; William J Sasiela; Robert Pordy; Scott Mellis; Hayes Dansky; Daniel A Gipe; Richard L Dunbar
Journal:  Circulation       Date:  2019-06-27       Impact factor: 29.690

9.  Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes.

Authors:  Jeffrey C Barrett; David G Clayton; Patrick Concannon; Beena Akolkar; Jason D Cooper; Henry A Erlich; Cécile Julier; Grant Morahan; Jørn Nerup; Concepcion Nierras; Vincent Plagnol; Flemming Pociot; Helen Schuilenburg; Deborah J Smyth; Helen Stevens; John A Todd; Neil M Walker; Stephen S Rich
Journal:  Nat Genet       Date:  2009-05-10       Impact factor: 38.330

10.  A genomic exploration identifies mechanisms that may explain adverse cardiovascular effects of COX-2 inhibitors.

Authors:  Ingrid Brænne; Christina Willenborg; Vinicius Tragante; Thorsten Kessler; Lingyao Zeng; Benedikt Reiz; Mariana Kleinecke; Simon von Ameln; Cristen J Willer; Markku Laakso; Philipp S Wild; Tanja Zeller; Lars Wallentin; Paul W Franks; Veikko Salomaa; Abbas Dehghan; Thomas Meitinger; Nilesh J Samani; Folkert W Asselbergs; Jeanette Erdmann; Heribert Schunkert
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

View more
  1 in total

Review 1.  The genetic interactions between non-alcoholic fatty liver disease and cardiovascular diseases.

Authors:  Nicholas W S Chew; Bryan Chong; Cheng Han Ng; Gwyneth Kong; Yip Han Chin; Wang Xiao; Mick Lee; Yock Young Dan; Mark D Muthiah; Roger Foo
Journal:  Front Genet       Date:  2022-08-10       Impact factor: 4.772

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.